Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015:2015:712507.
doi: 10.1155/2015/712507. Epub 2015 Sep 10.

The Rise and Fall of Hyaluronan in Respiratory Diseases

Affiliations
Review

The Rise and Fall of Hyaluronan in Respiratory Diseases

Mark E Lauer et al. Int J Cell Biol. 2015.

Abstract

In normal airways, hyaluronan (HA) matrices are primarily located within the airway submucosa, pulmonary vasculature walls, and, to a lesser extent, the alveoli. Following pulmonary injury, elevated levels of HA matrices accumulate in these regions, and in respiratory secretions, correlating with the extent of injury. Animal models have provided important insight into the role of HA in the onset of pulmonary injury and repair, generally indicating that the induction of HA synthesis is an early event typically preceding fibrosis. The HA that accumulates in inflamed airways is of a high molecular weight (>1600 kDa) but can be broken down into smaller fragments (<150 kDa) by inflammatory and disease-related mechanisms that have profound effects on HA pathobiology. During inflammation in the airways, HA is often covalently modified with heavy chains from inter-alpha-inhibitor via the enzyme tumor-necrosis-factor-stimulated-gene-6 (TSG-6) and this modification promotes the interaction of leukocytes with HA matrices at sites of inflammation. The clearance of HA and its return to normal levels is essential for the proper resolution of inflammation. These data portray HA matrices as an important component of normal airway physiology and illustrate its integral roles during tissue injury and repair among a variety of respiratory diseases.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overview of hyaluronan in respiratory disease: the lung is continuously exposed to external stimuli which can then impact HA synthesis and turnover. Factors such as type of stimuli, genetics, and the lung environment itself determine if resolution or persistent inflammation and HA changes persist.
Figure 2
Figure 2
Mechanistic role of HA in the response to lung injury: lung injury leads to the synthesis of HA that accumulates in the peribronchial and perivascular spaces. The ongoing inflammation leads to the generation of heavy-chain-HA (HC-HA) complexes mediated via TSG-6 which is a bottleneck in the pathological transformation of HA matrices. These HC-HA complexes can be degraded into smaller LMW fragments which engage cell receptors such as CD44, TLR4, and TLR2 and create downstream biological effects like fibrosis, AHR, and inflammation.

Similar articles

Cited by

References

    1. Petrey A. C., de la Motte C. A. Hyaluronan, a crucial regulator of inflammation. Frontiers in Immunology. 2014;5, article 101 doi: 10.3389/fimmu.2014.00101. - DOI - PMC - PubMed
    1. Wang A., de la Motte C., Lauer M., Hascall V. Hyaluronan matrices in pathobiological processes. FEBS Journal. 2011;278(9):1412–1418. doi: 10.1111/j.1742-4658.2011.08069.x. - DOI - PMC - PubMed
    1. Frey H., Schroeder N., Manon-Jensen T., Iozzo R. V., Schaefer L. Biological interplay between proteoglycans and their innate immune receptors in inflammation. The FEBS Journal. 2013;280(10):2165–2179. doi: 10.1111/febs.12145. - DOI - PMC - PubMed
    1. Wight T. N., Kang I., Merrilees M. J. Versican and the control of inflammation. Matrix Biology. 2014;35:152–161. doi: 10.1016/j.matbio.2014.01.015. - DOI - PMC - PubMed
    1. Vigetti D., Karousou E., Viola M., Deleonibus S., de Luca G., Passi A. Hyaluronan: biosynthesis and signaling. Biochimica et Biophysica Acta—General Subjects. 2014;1840:2452–2459. doi: 10.1016/j.bbagen.2014.02.001. - DOI - PubMed